Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "9333-1"

Looking for quality documents?
external link icon
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008 Results
external link icon
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
external link icon
Karen A. Dawes Elected as Repligen Co-chairperson of the Board of Directors
external link icon
Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging
external link icon
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
store icon
PharmaPure Tubing – Repligen
PharmaPure Tubing
external link icon
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $203.06 per share of Repligen’s common stock, which represents a conversion